7 Star MIT + Boost Tablets (225mg – 5 Count)
$37.99
| Title | Default Title |
|---|
7 Star MIT + Boost Tablets (225mg – 5 Count) take a different route from the rest of the 7 Star wall: five star-imprinted tablets pairing mitragynine-based Mitragyna speciosa extract with the brand’s Boost formulation, at 45mg of total active ingredients per tablet and 225mg per pack. Each tablet is built as two servings, and each serving combines 15mg paraxanthine, 5mg Mitragyna speciosa extract, and 2.5mg black pepper fruit extract.
The gold-toned card carries the same scratch-verify QR authentication as 7 Star’s 7-OH line, with the 225MG PER PACK flag and per-tablet breakdown printed on the front. Unflavored, net wt 3.2g.
- 45mg Actives Per Tablet: Mitragyna speciosa extract plus the Boost formulation, two servings per tablet
- Boost Formula: 15mg paraxanthine, 5mg Mitragyna speciosa extract, and 2.5mg black pepper fruit extract per serving
- 225mg Per Pack: Five tablets in a display blister, totals printed on the face
- Scratch-Verify QR: On-pack code confirms authenticity with the brand
- Star-Imprint Press: Each tablet stamped with the 7 Star mark
- Unflavored: Clean formulation with no added flavor system
MAECENAS IACULIS
Vestibulum curae torquent diam diam commodo parturient penatibus nunc dui adipiscing convallis bulum parturient suspendisse parturient a.Parturient in parturient scelerisque nibh lectus quam a natoque adipiscing a vestibulum hendrerit et pharetra fames nunc natoque dui.
ADIPISCING CONVALLIS BULUM
- Vestibulum penatibus nunc dui adipiscing convallis bulum parturient suspendisse.
- Abitur parturient praesent lectus quam a natoque adipiscing a vestibulum hendre.
- Diam parturient dictumst parturient scelerisque nibh lectus.
Scelerisque adipiscing bibendum sem vestibulum et in a a a purus lectus faucibus lobortis tincidunt purus lectus nisl class eros.Condimentum a et ullamcorper dictumst mus et tristique elementum nam inceptos hac parturient scelerisque vestibulum amet elit ut volutpat.
Reviews
There are no reviews yet.